Dr. Robison is the Chief Medical Officer of Novamind, a mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. He is a founding board member at Psychedelic Institute, a non-profit dedicated to compassionate access to psychedelic therapies. He is the Medical Director at Center for Change, one of the top eating disorder treatment centers worldwide. He serves as Coordinating Investigator of the Multidisciplinary Association for Psychedelic Studies (MAPS) MDMA-assisted psychotherapy study of eating disorders, supervising the training and clinical research of all the MDMA therapy sites. He is also an adjunct professor at both the University of Utah and BYU.
After residency and fellowship training, Dr. Robison joined the tenure-track faculty at the University of Utah where he conducted trials of neuropsychiatric medicines and co-directed a genetics lab. After leaving full-time academia, he founded a Phase I-IV CNS clinical trials site and served as its PI for five years until he sold the company. Dr. Robison has extensive experience with ketamine in both research and clinic settings; he conducted his first research study with ketamine in 2011. A board-certified psychiatrist, he completed undergraduate studies in neuroscience at BYU then went to the University of Utah where he earned both his medical and MBA degrees.